English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Hepatitis B Virus (HBV) increases the risk of liver diseases and when there is coinfection with Human Immunodeficiency Virus (HIV) that will increase the risk of hepatotoxicity because of frequent use of antiretroviral treatments. They share several routes of transmission as both HIV and HBV spread from person to person in semen, blood, or other body fluids. Globally, approximately 90% of infected patients were infected with HBV, and Hepatitis B Surface Antigen (HBsAg) was detected in the 15% of HIV positive individuals [1]. They both share certain epidemiological characteristics such as their mode of transmission and the population that is at higher risk of infections. The seroprevalence of HBV in those infected with HIV ranges between 6.3% and 39% [2]. Furthermore, chronic hepatitis B mortality rate increases because of HIV and it will progress faster to liver cirrhosis and hepatocellular carcinoma. HIV patients who contacted HBV suffered from low HBsAg seroconversion with high levels of HBV DNA [3].

Seroprevalence of Hepatitis B Virus in HIV Tested Positive Patients Accessing Treatment in Specialist Hospital Jimeta